Skip Ribbon Commands Skip to main content

CT2 Program Lecture Series

All lectures are on Tuesdays from 12 to 1 p.m. in Comer Commons at Moores Cancer Center (directions and map). Lunch is available at 11:45 a.m. for those attending the lecture. 

Principles of Cancer Drug Therapeutics Development

This is a required series of 12 weekly lectures delivered by CT2 and UC San Diego faculty members during fall quarter. They focus on the necessary sequential steps in drug development.

Topics in Cancer Drug Development

This is a series of 10 monthly lectures by industry leaders in cancer drug development. The goal is to expose trainees to experts with a substantial track record in the “real life” challenges of cancer drug development. The lecturers are typically CEOs, directors of research, or medical directors from companies in the San Diego biomedical community, although experts from large pharmaceutical companies have also participated. The outside speakers are invited to discuss challenges of developing a given target or novel therapeutic and give fellows an opportunity to hear the story of the development of specific therapeutic agents.

2015-2016 Lecture Series
Printable version

Date Speaker Affiliation Title Location
1/19/16 Peter Worland Celgene Drug Discovery Not Discussed Comer Commons
1/26/16 Scott Weinrich
Jennifer LaFontaine
(Dwayne Stupack, PhD, will host)
Pfizer Drug Discovery: Chemistry and Biology Comer Commons
2/2/16 TBA TBA TBA Comer Commons
2/9/16 Silvio Gutkind, MD Moores Cancer Center TBA Comer Commons
2/16/16 Deepak Dalvie, PhD Pfizer Pharmacokinetics and Metabolism Comer Commons
2/23/16 Ezra Cohen, MD Moores Cancer Center TBA Comer Commons
3/1/16 Charles Theuer, MD, PhD
(Ezra Cohen, MD, will host)
Tracon Pharmaceuticals TBA Comer Commons
3/8/16 Robert Herschberg VentiRx TBA Comer Commons
3/15/16 Scott Lippman, MD Moores Cancer Center Personalizing prevention and therapy:
The challenge of head and neck cancer
Comer Commons
3/22/16 Greg Stevens and Laurie Strawn Pfizer Drug safety and regulatory Comer Commons
3/29/16 Dan Shoemaker Fate Therapeutics TBA Comer Commons
4/5/16 Hakan Sakul Pfizer Precision Medicine and Diagnostics Comer Commons
4/12/16 Liangfang Zhang, PhD Moores Cancer Center TBA Comer Commons
4/19/16 TBA TBA TBA Comer Commons
4/26/16 Dan Gold MeiPharma TBA Comer Commons
5/3/16 Jon Cheng Merck Pembrolizumab: Harnessing the power of the immune system to fight cancer Comer Commons
5/10/16 Diane Boucher, MD Vertex TBA Comer Commons
5/17/16 Eric Murphy Crown Bioscience TBA Comer Commons
5/24/16 TBA TBA TBA Comer Commons
5/31/16   TBA TBA TBA Comer Commons

Schedules for previous years